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Abstract
Objective To assess the efficacy of vitamin and antioxidant supplements
in the prevention of cardiovascular diseases.
Design Meta-analysis of randomised controlled trials.
Data sources and study selection PubMed, EMBASE, the Cochrane
Library, Scopus, CINAHL, and ClinicalTrials.gov searched in June and
November 2012. Two authors independently reviewed and selected
eligible randomised controlled trials, based on predetermined selection
criteria.
Results Out of 2240 articles retrieved from databases and relevant
bibliographies, 50 randomised controlled trials with 294 478 participants
(156 663 in intervention groups and 137 815 in control groups) were
included in the final analyses. In a fixed effect meta-analysis of the 50
trials, supplementation with vitamins and antioxidants was not associated
with reductions in the risk of major cardiovascular events (relative risk
1.00, 95% confidence interval 0.98 to 1.02; I2=42%). Overall, there was
no beneficial effect of these supplements in the subgroup meta-analyses
by type of prevention, type of vitamins and antioxidants, type of
cardiovascular outcomes, study design, methodological quality, duration
of treatment, funding source, provider of supplements, type of control,
number of participants in each trial, and supplements given singly or in
combination with other supplements. Among the subgroupmeta-analyses
by type of cardiovascular outcomes, vitamin and antioxidant
supplementation was associated with a marginally increased risk of
angina pectoris, while low dose vitamin B6 supplementation was
associated with a slightly decreased risk of major cardiovascular events.
Those beneficial or harmful effects disappeared in subgroup
meta-analysis of high quality randomised controlled trials within each
category. Also, even though supplementation with vitamin B6 was
associated with a decreased risk of cardiovascular death in high quality
trials, and vitamin E supplementation with a decreased risk of myocardial
infarction, those beneficial effects were seen only in randomised
controlled trials in which the supplements were supplied by the
pharmaceutical industry.
Conclusion There is no evidence to support the use of vitamin and
antioxidant supplements for prevention of cardiovascular diseases.
Introduction
Cardiovascular diseases are the leading causes of deaths and
disability worldwide.1Over the past few decades, observational
epidemiological studies have reported that intake of fruit and
vegetables rich in various vitamins and antioxidants reduce the
risk.2 It has been estimated that if an individual increases fruit
and vegetable intake up to 600 g daily, the worldwide burden
of disease could be reduced by 31% for ischaemic heart disease
and 19 % for ischaemic stroke.3 Unlike the evidence for fruit
and vegetables, however, many randomised controlled trials
have reported inconsistent findings regarding the efficacy of
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vitamin and antioxidant supplementation on cardiovascular
diseases.4
Several meta-analyses have reported conflicting evidence from
randomised controlled trials. In 2003, a meta-analysis of 12
trials indicated that vitamin E supplements did not provide
benefit in cardiovascular death or cerebrovascular events.5
Instead, it showed that β carotene supplementation led to a small
increase in all cause mortality and cardiovascular death. In 2006,
Flores-Mateo et al reported that the use of supplements
containing selenium did not reduce the risk of coronary heart
disease in the meta-analysis of six trials.6 More recently,
however, Lee et al found that folic acid supplementation with
B vitamins had potential small benefits in the prevention of
stroke,7 and Qin et al indicated that folic acid treatment
decreased the risk of cardiovascular disease by 15% in patients
with end stage renal disease or advanced chronic kidney disease.8
Even though several meta-analyses of randomised controlled
trials have been published regarding the efficacy of vitamins
and antioxidant supplements on cardiovascular diseases, they
involved individual vitamins or antioxidants, and there was no
published comprehensive meta-analysis that reviewed this topic
all together in one report. To the best of our knowledge, no
meta-analyses have performed subgroup analyses by important
factors such as methodological quality or funding source.
We investigated the efficacy of vitamin and antioxidant
supplements on cardiovascular diseases through a
comprehensive meta-analysis of randomised controlled trials
by various factors such as by type of prevention (primary v
secondary), type of vitamins and antioxidants, dose of
supplement, type of cardiovascular outcomes, study design,
methodological quality (high v low), duration of treatment (<5
years v ≥5 years), funding source (independent organisation v
pharmaceutical industry), provider of supplements
(pharmaceutical industry v not pharmaceutical industry), type
of control (placebo v no placebo), number of participants in
each trial (<10 000 v ≥10 000), and supplements given singly
or in combination with other vitamin or antioxidant supplements.
Methods
Literature search
We searched PubMed, Embase, the Cochrane Library, Scopus,
CINAHL, and ClinicalTrials.gov in June and November 2012
using common keywords related to vitamin or antioxidant
supplements and cardiovascular diseases. The keywords were
as follows: “vitamin supplement,” “antioxidant supplement,”
“vitamin A supplement,” “vitamin B6 supplement,” “vitamin
B12 supplement,” “folic acid supplement,” “vitamin C
supplement,” “vitamin D supplement,” “vitamin E supplement,”
“selenium supplement,” “beta-carotene supplement,” “lycopene
supplement,” or “isoflavone supplement,”; and “cardiovascular
disease,” “angina,” “acute myocardial infarction,” “transient
ischemic attack,” or “stroke.” We also reviewed the
bibliographies of relevant articles to locate additional
publications. The language of publication was not restricted.
Selection criteria
To be included randomised controlled trials had to report the
efficacy of vitamin or antioxidant supplements for the prevention
of cardiovascular diseases and follow participants for at least
six months. If data were duplicated or shared in more than one
study, we included the first published or more comprehensive
study in the analysis.
Selection of relevant studies
Based on the predetermined selection criteria, two of the authors
(S-KM,WJ) independently selected all trials retrieved from the
databases and bibliographies. Disagreements were resolved by
discussion or in consultation with a third author (S-WO).
Assessment of methodological quality
We assessed the methodological quality of included trials with
the Jadad scale.9 Its score ranges from 0 (very poor) to 5
(rigorous). The five point quality scale consists of points for
randomisation (described as randomised, 1 point; table of
random numbers or computer generated randomisation,
additional 1 point), double blind (described as double blind, 1
point; use masking such as identical placebo, additional 1 point),
and follow-up (state the numbers and reasons for withdrawal
in each group; 1 point) in the report of each trial. All trials were
classified into two groups, those with a score of ≤4 or versus 5
because the mean score for the 47 trials assessed in the current
study (the full text for three trials was not available) was 4.3,
and then subgroup meta-analyses were performed.
Main and subgroup analyses
We investigated the association between vitamin or antioxidants
supplementation and major cardiovascular events. Major
cardiovascular events included cardiovascular death, fatal or
non-fatal myocardial infarction, angina, sudden cardiac death,
fatal or non-fatal stroke, and transient ischaemic attack.We also
performed subgroup meta-analyses by type of prevention
(primary v secondary: in this study, trials involving healthy
populations or patients with any specific disease except for
cardiovascular disease were classified as primary prevention
trials, and trials involving patients with cardiovascular disease
were classified as secondary prevention trials), type of
supplement by quality and dose (each supplement, vitamins
only, antioxidants only, or antioxidants excluding vitamins),
type of outcome (cardiovascular death, angina, fatal or non-fatal
myocardial infarction, stroke, or transient ischaemic attack),
type of outcome in each supplement, type of study design
(randomised, double blind, placebo controlled trial v open label,
randomised controlled trial), methodological quality (high v
low), duration of treatment (<5 years v≥5 years), funding source
(pharmaceutical industry v independent organisation), provider
of supplements (pharmaceutical industry v not pharmaceutical
industry), type of control (placebo v no placebo), number of
participants (≥10 000 v <10 000), and supplements given singly
or in combination with other vitamin or antioxidant supplements
by quality.
Statistical analysis
We calculated the relative risks with 95% confidence intervals
by using crude 2×2 tables on the basis of intention to treat
analysis, whenever possible, from the original publications. For
the test of heterogeneity, we used Higgins I2, which measures
the percentage of total variation across trials.10 I2was calculated
as follows:
I2 = 100% × (Q – df)/Q,
where Q is Cochran’s heterogeneity statistic and df indicates
the degrees of freedom. Negative values of I2 are set to zero. I2
ranges from 0% (no observed heterogeneity) to 100% (maximal
heterogeneity).
To calculate pooled relative risks with 95% confidence intervals,
we used both the fixed effects and random effects models. An
I2 value >50% was considered as substantial heterogeneity.
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When there was no substantial heterogeneity, we reported the
pooled estimate calculated from the fixed effects model. When
there was substantial heterogeneity, we reported the pooled
estimate calculated from the random effects model.
We assessed publication bias with Begg’s funnel plot and
Egger’s test. If publication bias exists, the Begg’s funnel plot
is asymmetric or the Egger’s test P value is <0.05. We used
Stata SE version 10.0 software (StataCorp, College Station, TX)
for all the statistical analyses.
Results
By searching databases (PubMed, Embase, the Cochrane
Library, Scopus, CINAHL, and ClinicalTrials.gov) and hand
searching relevant bibliographies, we identified 2240 articles
(fig 1⇓). After excluding 573 duplicated articles, two of authors
independently reviewed and excluded 1593 articles that did not
satisfy the predetermined selection criteria based on each
article’s title and abstract. We reviewed the full texts of the 74
remaining articles and excluded 24 articles (16 were identical
trials within the same population; five were not related to the
subject of this study; two were replies or comments; and one
reported insufficient data). A total of 5011-60 trials were included
in the final analysis. The full details of all included trials are in
appendix 1. The 50 trials included 294 478 participants with
156 663 in intervention groups and 137 815 in control groups.
In the trials reporting age, the mean age of the participants
ranged from 49 to 82. The year of publication of the included
trials ranged between 1989 and 2012, spanning 23 years. Twelve
trials were conducted in the United State, four in the United
Kingdom, three in Finland, three in France, three in Italy, two
in Canada, two in Israel, two in Australia, two in China, two in
Germany, two in Norway, one in Sweden, one in Switzerland,
one in the Netherlands, one in US/Canada, one in
US/Canada/Scotland), one in Germany/the Netherlands, one in
Canada/US, one in 13 countries, and one in 20 countries. The
range of supplementation and follow-up periods was 6 months
to 12 years. The number of participants ranged from 61 to 39
876.
Among the 50 trials, 30 were primary prevention trials (general
populations, smokers and workers exposed to asbestos, patients
with oesophageal dysplasia, male physicians, patients with
non-melanoma skin cancer, postmenopausal women, patients
undergoing chronic haemodialysis, patients with end stage renal
disease, ambulatory elderly women with vitamin D
insufficiency, patients with chronic renal failure, older people
with femoral neck fractures, patients with diabetes mellitus,
elderly women with a low serum 25-hydroxyvitamin D
concentration, health professionals, people with a high fasting
plasma total homocysteine concentration, or kidney transplant
recipients), and 20 were secondary prevention trials (patients
with cardiovascular disease, coronary heart disease, acute
myocardial infarction, unstable angina, transient ischaemic
attack, stroke, angiographically proved coronary atherosclerosis,
vascular disease, or aortic valve stenosis).
Forty five trials were randomised, double blind, placebo
controlled trials, and five were open label, randomised controlled
trials. All vitamin or antioxidant supplements and placebos were
administered orally either singly or in combination with other
vitamin or antioxidant supplements.
The dose regimens used in each trial were as follows: vitamin
A (10 000 or 25 000 IU daily), vitamin B6 (3, 6, 10, 12.5, 25,
40, 48, 50, or 100 mg daily; 20 mg three times weekly), vitamin
B12 (0.4, 0.5, 1, or 2 mg daily; 6, 18, 20, 60, or 400 µg daily; 50
µg three times weekly), vitamin C (60, 120, 180, 250, 500, or
1000 mg daily), vitamin D (800 or 1000 IU daily; 200 IU twice
daily; 400 IU twice daily; 300 IU daily and 100 IU daily; 100
000 IU every four months), vitamin E (60, 200, 400, 600, 800
IU daily; 400 or 600 IU alternate day; 400 IU twice daily; 30,
50, 300, 600 mg daily), β carotene (6, 15, 20, 25, 30, or 50 mg
daily; 50 mg alternate day), folic acid (560 or 800 µg daily; 0.5,
0.8, 1, 1.2, 2, 2.5, 5, 15, or 40 mg daily; 5 mg three times
weekly), and selenium (50, 75, 100, 122, or 122 µg daily).
Thirty nine trials used vitamin supplements only, and 22 trials
used antioxidant supplements only. The additional nutritional
supplements or drugs used in each trial were aspirin (325 mg
daily); coenzyme Q10 (100 mg daily); calcium (93 mg daily)
with or without hormone replacement therapy; application of a
sun protection factor 15+ sunscreen; ramipril (angiotensin
converting enzyme inhibitor; with or without aspirin (100 mg
daily); zinc (20 mg daily); multivitamins and minerals; calcium
carbonate (500 mg twice daily); calcium (1000 mg daily);
calcium citrate (1000 mg daily); omega 3 fatty acids
(eicosapentaenoic acid and docosahexaenoic acid at a ratio of
2:1). The main outcomes used in each trial were fatal or
non-fatal acute myocardial infarction, unstable angina, coronary
heart disease, ischaemic heart disease, major coronary events,
cardiovascular death, sudden death, transient ischaemic stroke,
stroke, and cardiovascular disease.
Out of 47 trials reporting funding source, five were funded by
pharmaceutical companies and 42were fundedmainly by public
or governmental organisations or independent scientific
foundations. Also, in 29 trials, vitamin or antioxidant
supplements were provided at no cost from the pharmaceutical
industry, while 18 trials paid for them or did not mention
whether the pharmaceutical industry charged for them.
In the fixed effects meta-analysis of all 50 trials, use of vitamin
or antioxidant supplements was not associated with reduced
risks of major cardiovascular events (relative risk 1.00; 95%
confidence interval 0.98 to 1.02; I2=42%) (fig 2⇓). Overall, the
effect sizes of the smaller randomised controlled trials tend to
be less than 1.0, while the effect sizes of the larger ones tend to
be null. In the 48 selected trials, the Begg’s funnel plot was
symmetrical, and P for bias was 0.11 in the Egger’s test (two12 22
of the 50 trials were not included because of “zero” cells in the
2×2 table) (the Begg’s funnel plot is not shown in the figure).
Based on the Jadad scales, the mean score for the 47 trials
assessed was 4.3, ranging from 2 to 5 (table 1⇓).
Tables 2-4⇓⇓⇓ show the efficacy of vitamin or antioxidant
supplements in the prevention of themajor cardiovascular events
in subgroupmeta-analysis by various factors. Overall, subgroup
meta-analyses by type of supplement (table 2)⇓ showed that
there was no significant association between vitamin or
antioxidant supplements and the risk of the major cardiovascular
events (figs 3-6,⇓⇓⇓⇓ and table 2⇓), while low dose vitamin B6
supplementation slightly decreased the risk of major
cardiovascular events (relative risk 0.92, 95% confidence
interval 0.85 to 0.99; I2=35%; fig 7⇓) in the fixed effects
meta-analysis. Similarly, we found no significant association
in the overall subgroup meta-analysis by type of outcome
(cardiovascular death, fatal or nonfatal myocardial infarction,
stroke, or transient ischaemic attack; table 3⇓), type of
prevention (primary v secondary; table 2⇓), type of study design,
methodological quality (high v low by score of 5), duration of
treatment (<5 years v ≥5 years), funding source (independent
organisation v pharmaceutical industry) (table 4⇓), and provider
of the supplements (pharmaceutical industry v at cost or no
mention), while vitamin B6 and vitamin E supplements were
associated with a reduced risk of cardiovascular death (relative
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risk 0.91, 95% confidence interval 0.83 to 0.99; I2=0%) and
myocardial infarction (0.77, 0.65 to 0.91; I2=76%), respectively,
and vitamin and antioxidant supplementation marginally
increased the risk of angina pectoris (1.04, 1.00 to 1.08; I2=36%)
(table 3⇓).
In the subgroup meta-analysis of high quality randomised
controlled trials within each category of low dose vitamin B6
(relative risk 0.94, 95% confidence interval 0.87 to 1.02;
I2=39%; fixed effects model, table 2⇓ and fig 7⇓) and angina
(1.01, 0.86 to 1.18; I2=57%; random effects model, table 3⇓),
however, beneficial or harmful effects disappeared. Also, even
though vitamin B6 supplementation was associated with
decreased risks of cardiovascular death in high quality trials,
and vitamin E supplementation with a decreased risk of
myocardial infarction, those beneficial effects were seen only
in trials supplied with supplements by pharmaceutical industry
(fig 8⇓ and table 3⇓).
In the subgroup meta-analysis by the number of participants in
each trial, vitamin or antioxidant supplements showed a trend
toward a decreased (but not significant) risk of major
cardiovascular events (relative risk 0.97, 95% confidence
interval 0.94 to 1.01; I2=40%) in the subgroup meta-analysis of
trials with <10 000 participants, while those supplements showed
an increased (but not significant) risk of themajor cardiovascular
events (1.02, 0.99 to 1.04; I2=39%) in the subgroup
meta-analysis of those with ≥10 000 participants (table 4⇓).
Table 5⇓ shows the efficacy of vitamin and antioxidant
supplements given singly or in combination with other vitamin
or antioxidant supplements on major cardiovascular events in
subgroup meta-analyses. We found no significant beneficial
effect of vitamin and antioxidant supplements in most of the
subgroup meta-analyses, while only vitamin E supplements had
a marginally significant decreased efficacy for the major
cardiovascular events in high quality trials (relative risk 0.95,
95% confidence interval 0.90 to 1.00; I2=45%).
Discussion
Summary of main findings
In this large scale meta-analysis of randomised controlled trials,
we found no evidence to support the use of vitamin or
antioxidant supplements for the primary or secondary prevention
of major cardiovascular events. Furthermore, these supplements
were not associated with any reduced risk of the such events in
the subgroup meta-analyses according to various factors such
as type of vitamins and antioxidants, type of cardiovascular
outcomes, study design, methodological quality, duration of
treatment, funding source, provider of supplements, type of
control, number of participants in each trial, and supplements
given singly or in combination with other vitamins or antioxidant
supplements.
Strengths of the current meta-analysis
Our main findings are consistent with those of previous
meta-analyses that investigated the association between the use
of vitamin B,7 61 62 vitamin D,63 vitamin E,5 64 65 β carotene,5 folic
acid,7 8 61 62 66 or selenium6 and cardiovascular diseases in
randomised controlled trials.
Our findings, however, are inconsistent with those of previous
in vivo animal studies that suggested vitamins or antioxidants
inhibit the development of atherosclerosis67-70 and in vitro
laboratory studies that indicated vitamins and antioxidants
reduce lipid peroxidation and free radical damage, and finally
inhibit atheroslcerosis.71-73 The findings from animal and
laboratory studies are associated with the oxidative modification
hypothesis of atherosclerosis. This hypothesis, which claims
that the oxidation of low density lipoprotein cholesterol initiates
atherosclerosis, could explain these associations.70 It suggests
that accumulated low density lipoprotein in the subendothelial
space of arteries is oxidised to minimally modified low density
lipoprotein by vascular cells, which then induces accumulation
of monocytes and macrophages, which stimulate further
peroxdiation of low density lipoprotein.74 This reaction makes
oxidised low density lipoprotein more negatively charged and
completely oxidised.75 The uptake of completely oxidised low
density lipoprotein leads to massive uptake of cholesterol by
the macrophages.70 It also stimulates the binding of monocytes
to the endothelium, promotes the release of lipids and lysosomal
enzymes, and thus enhances the progression of
atherosclerosis.70 76
Our meta-analysis indicates that there is a discrepancy in
findings between in vivo animal or in vitro laboratory studies
and randomised controlled trials with regard to the association
between vitamin or antioxidants (natural forms in fruit and
vegetables or synthetic forms) and cardiovascular disease.
Several theories could explain this discrepancy. Firstly,
preclinical studies such as animal studies and in vitro laboratory
studies might not represent the biological processes in the human
body.73 Thus, even though vitamins or antioxidant substances
show benefits against a certain disease in preclinical studies,
they might show no benefit or could be harmful under clinical
circumstances. Secondly, the beneficial effects of vitamin or
antioxidant supplements might be related to the timing of their
administration. For example, the beneficial effects vitamin C
occur in the early stages of atherosclerosis,73 and once the
atherosclerotic plaque has developed it has no beneficial effect.77
In the trials we included in our analysis, the mean age of
participants ranged from 49 to 82, the ages at which
atherosclerotic plaques or changes might be already formed.73
We found a similar discrepancy in findings between case-control
studies and randomised controlled trials. This could be explained
by methodological biases of case-control studies. Case-control
studies use retrospective assessment of each participant’s
information on fruit and vegetable consumption and are thus
susceptible to two potential biases: recall and selection.
Even though cohort studies are less biased than case-control
studies, some important methodological issues might explain
the differences in findings between cohort studies and
randomised controlled trials. The diet assessment tools such as
the food frequency questionnaire might not precisely assess an
individual’s long term diet or might not provide sufficient
information on fruit and vegetable consumption. Also, andmore
importantly, the use of vitamin or antioxidant supplements in
randomised controlled trials should not be seen as equivalent
to the intake of fruit and vegetables in cohort studies, which
contain other various micronutrients as well as specific
nutritional substances. Beneficial effects of vitamin or
antioxidant supplements on cardiovascular disease might be
obtained from the combination of various nutrients, not from
one or several specific nutrients.
Strengths andweaknesses in relation to other
meta-analyses
Our findings are similar to those of the previous meta-analysis
of randomised controlled trials on the association between
vitamin or antioxidant supplementation and other outcomes
such as mortality and cancer. In 2007, Bjelakovic et al reported
that vitamin A, vitamin E, or β carotene supplements were
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associated with increased mortality in a meta-analysis of 47 low
bias (high quality) trials with 180 938 participants, while vitamin
C and seleniumwere not associated with mortality.78Regarding
the negative effect of antioxidant supplements on mortality,
they suggested that the elimination of free radicals in the human
body through antioxidant supplementation interferes with
essential defensivemechanisms such as apoptosis, phagocytosis,
and detoxification and might lead to an increased mortality.78
Their updated meta-analysis including the recently published
trials had similar findings on this issue and suggested that
antioxidant supplements should be considered as medicinal
products and should undergo sufficient evaluation before they
are marketed.79 In 2010, Myung et al reported that antioxidant
supplements had no primary or secondary preventive effect on
cancer and even increased the risk of bladder cancer in a
meta-analysis of 22 randomised controlled trials.80
Because of these discrepancies in results between preclinical
studies and clinical trials, the findings from preclinical studies
on the effects or actions of vitamin or antioxidant substances
should not be directly applied to humans.
In the meantime, when we performed subgroup meta-analyses
by quality (high v low), dose (low v high), and supplements
given singly or in combination with other supplements, we
found no overall association between vitamin or antioxidant
supplements and the risk of major cardiovascular events, while
vitamin and antioxidant supplementation were associated with
a marginally increased risk of angina pectoris, and low dose
vitamin B6 supplementation with a slightly decreased risk of
major cardiovascular events. In the subgroup meta-analysis of
high quality randomised controlled trials within each category,
however, beneficial or harmful effects disappeared. We cannot
therefore conclude that vitamin and antioxidant supplements
are harmful for angina pectoris or that vitamin B6 supplements
are beneficial for major cardiovascular events. Also, even though
vitamin B6 supplementation was associated with a decreased
risk of cardiovascular mortality in high quality trials, and vitamin
E supplementation was associated with a decreased risk of
myocardial infarction, those beneficial effects were shown only
in trials with supplements provided by the pharmaceutical
industry. So we cannot completely exclude the possibility that
this might have influenced the respective trial design, results,
or interpretations.
We also found that there was a trend toward an increased (not
significant) risk of major cardiovascular events for the
supplementation group in subgroup meta-analysis of trials with
≥10 000 participants, while there was a trend toward a decreased
(not significant) risk in subgroup meta-analysis of trials with
<10 000 participants. Given that a larger sample size is more
accurate than a smaller size, we cannot exclude that vitamin or
antioxidant supplementation might be associated with an
increase in the risk of cardiovascular disease. Further large scale
trials are needed to confirm this.
Weaknesses of the current meta-analysis
There are several limitations in the current study. Firstly, we
investigated the association only between synthetic vitamin and
antioxidant supplements and cardiovascular disease. Thus, our
findings could not be directly applied to fruit and vegetables
rich in natural vitamins or antioxidants or natural vitamins
derived or extracted from plants. Secondly, we were unable to
evaluate whether vitamin and antioxidant supplementationwould
be beneficial against cardiovascular disease for populations who
are deficient in vitamins or antioxidants at baseline. Further
randomised controlled trials in those populations are needed.
Thirdly, we used the Jadad scale to assess the methodological
quality of the trials, which has been criticised because it is
subject to the generic problems of scales, has a strong emphasis
on reporting rather than conduct, and does not cover
concealment of allocation, one of the important biases in
randomised controlled trials.81 As an alternative, the Cochrane
Risk of Bias (RoB) tool has been used to evaluate internal
validity of randomised controlled trials since 2008. Hartling et
al, however, reported that the inter-rater agreement varied
substantially across domains in the Cochrane tool, and it took
considerably longer to complete than the Jadad scale.82 Further
validated tools for the assessment of quality are needed. Finally,
we assessed the methodological quality of the trials based only
on the data presented in each article. Thus, we might not have
assessed the actual performance or biases of each trial.
Meaning of the findings
In summary, we found no evidence to support the use of vitamin
or antioxidant supplements in the prevention of cardiovascular
disease. Also, recent meta-analyses have shown that vitamin or
antioxidant supplements are associated with increased mortality
and have no preventive effect on cancer or were even associated
with increases in some types of cancer. Most countries permit
the pharmaceutical or food industry to sell these supplements
under the name of functional food or medical food, and many
people take vitamin or antioxidant supplements in the belief
that they improve their health. Based on recent meta-analyses
of randomised controlled trials, including the current study,
however, governments and regulating agencies for food and
drugs should consider vitamin and antioxidant supplements as
medicinal products and strictly evaluate their efficacy and safety
before marketing.
Unanswered questions and future research
Further randomised controlled trials are required to determine
whether vitamin and antioxidant supplementation would be
beneficial against cardiovascular disease for people who are
deficient in vitamins or antioxidants at baseline. Regarding the
assessment of methodological quality of each trial, further
validated tools that could assess the actual performance or biases
of each trial should be developed.
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What is already known on this topic
Over the past few decades, observational epidemiological studies have reported that intake of fruit and vegetables rich in various vitamins
and antioxidants is associated with a reduced risk of cardiovascular disease
Unlike the evidence for the benefits of fruit and vegetables, however, randomised controlled trials have had inconsistent results regarding
benefits of vitamin or antioxidant supplements
Even though several meta-analyses of randomised controlled trials have been published, those involved individual vitamin or antioxidant
supplements, and there has been no published comprehensive meta-analysis that reviewed this topic all at once in one report
What this study adds
This large scale meta-analysis of randomised controlled trials suggests that there is no evidence to support the use of vitamin or
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Governments and regulating agencies for food and drug should consider vitamin and antioxidant supplements as medicinal products
and strictly evaluate their efficacy and safety before marketing
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Tables
Table 1| Methodological quality, based on Jadad scale, of 47* included trials on efficacy of vitamin and antioxidant supplements in prevention
of cardiovascular diseases
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Table 1 (continued)






*We were unable to retrieve full text from three trials: Korpela et al, 1989,11Kuklinski et al, 1994,12and Rafiee et al, 2002.29
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Table 2| Efficacy of vitamin and antioxidant supplements in the prevention of the major cardiovascular events in subgroup meta-analysis
by type of prevention and type of supplement
ModelHeterogeneity I2 (%)Relative risk (95% CI)No of trialsFactor
Fixed effects421.00 (0.98 to 1.02)50All
Prevention:
Fixed effects421.01 (0.98 to 1.03)30Primary
Fixed effects441.00 (0.97 to 1.03)20Secondary
Type of supplement:
Fixed effects440.99 (0.97 to 1.01)39Vitamins only
Fixed effects320.99 (0.96 to 1.02)17Low quality trials
Random effects530.99 (0.94 to 1.05)22High quality trials
Fixed effects410.98 (0.96 to 1.02)22Antioxidants only
Fixed effects250.99 (0.96 to 1.03)11Low quality trials
Fixed effects490.97 (0.91 to 1.02)9High quality trial
Random effects870.98 (0.45 to 2.16)2Vitamin A
NANA0.63 (0.37 to 1.07)1Low dose (10 000 IU/day)
NANA1.41 (1.15 to 1.73)*1High dose (25 000 IU/day)
Fixed effects330.96 (0.92 to 1.01)16Vitamin B6
Fixed effects350.92 (0.85 to 0.99)*8Low dose (3-25 mg/day)
Fixed effects00.76 (0.61 to 0.94)*3Low quality trials
Fixed effects390.94 (0.87 to 1.02)5High quality trials
Fixed effects220.99 (0.94 to 1.05)8High dose (40-100 mg/day)
Fixed effects370.99 (0.95 to 1.02)17Vitamin B12
Fixed effects340.96 (0.90 to 1.02)11Low dose (6 µg-0.5 mg/day)
Fixed effects431.00 (0.96 to 1.05)6High dose (1-2 mg/day)
Fixed effects350.99 (0.95 to 1.02)21Folic acid
Fixed effects390.99 (0.96 to 1.03)17Low dose (500 µg-5 mg/day)
Fixed effects00.89 (0.78 to 1.03)4High dose (10-40 mg/day)
Fixed effects160.99 (0.94 to 1.04)7Vitamin C†
Fixed effects310.99 (0.94 to 1.04)3Low dose (120-250 mg/day)
Fixed effects280.98 (0.94 to 1.12)4High dose (500-1000 mg/day)
Fixed effects231.02 (0.98 to 1.07)7Vitamin D
Fixed effects01.05 (0.99 to 1.12)2Low dose (120-250 mg/day)
Fixed effects00.94 (0.86 to 1.03)5High dose (500-1000 mg/day)
Fixed effects440.97 (0.94 to 1.01)17Vitamin E†
Fixed effects350.96 (0.92 to 1.01)13Low dose (60 IU-250 mg/day)
Random effects690.84 (0.52 to 1.35)4High dose (500-600 mg/day)
Random effects551.04 (0.96 to 1.12)11β carotene
Fixed effects70.99 (0.95 to 1.03)6Low dose (6-25 mg/day)
Random effects691.14 (0.96 to 1.35)5High dose (30-50 mg/day)
Fixed effects470.91 (0.77 to 1.06)7Selenium
Fixed effects440.85 (0.70 to 1.04)5Low dose (50-100 µg/day)
Fixed effects670.57 (0.10 to 3.16)2High dose (122-200 µg /day)
NA=not applicable.
*P≤0.05.
†For subgroup meta-analysis of vitamin C and vitamin E, we used data from 2008 PHS2 article83 because data were not available in 2012 PHS article.
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Table 3| Efficacy of vitamin and antioxidant supplements in prevention of major cardiovascular events in subgroup meta-analysis by
outcome
ModelHeterogeneity I2 (%)Relative risk (95% CI)No of trials
Fixed effects411.01 (0.97 to 1.05)32Cardiovascular death
Random effects870.98 (0.45 to 2.16)2Vitamin A
Fixed effects00.91 (0.83 to 0.99)*8Vitamin B6
Fixed effects120.93 (0.75 to 1.14)4Low quality trials
Fixed effects00.90 (0.82 to 0.99)*4High quality trials
Fixed effects00.96 (0.84 to 1.10)2Not supplied by pharmaceutical industry
Fixed effects00.85 (0.75 to 0.97)*2Supplied by pharmaceutical industry
Fixed effects00.96 (0.83 to 1.10)3Not supplied by pharmaceutical industry
Fixed effects00.88 (0.79 to 0.98)*5Supplied by pharmaceutical industry
Fixed effects270.96 (0.90 to 1.03)9Vitamin B12
Fixed effects110.96 (0.89 to 1.03)11Folic acid
Fixed effects271.03 (0.95 to 1.12)6Vitamin C†
Fixed effects270.90 (0.76 to 1.07)3Vitamin D
Fixed effects370.98 (0.92 to 1.04)15Vitamin E†
Random effects611.10 (0.96 to 1.27)10β carotene
Fixed effects370.98 (0.92 to 1.04)15Selenium
Random effects870.98 (0.45 to 2.16)2Vitamin
Fixed effects361.04 (1.00 to 1.08)*10Angina
Fixed effects251.05 (1.00 to 1.09)*6Low quality trials
Random effects571.01 (0.86 to 1.18)4High quality trials
Random effects770.93 (0.72 to 1.20)4Vitamin B6
Random effects770.93 (0.72 to 1.20)4Vitamin B12
Random effects770.93 (0.72 to 1.20)4Folic acid
Fixed effects00.94 (0.85 to 1.03)2Vitamin C†
NANA1.07 (0.93 to 1.23)1Vitamin D
Fixed effects01.15 (0.99 to 1.33)3Vitamin E†
Fixed effects01.00 (0.96 to 1.03)34Myocardial infarction
Fixed effects110.99 (0.91 to 1.07)13Vitamin B6
Fixed effects40.99 (0.93 to 1.06)14Vitamin B12
Fixed effects00.99 (0.93 to 1.06)15Folic acid
Fixed effects00.96 (0.87 to 1.07)4Vitamin C†
Fixed effects01.06 (0.92 to 1.21)2Vitamin D
Random effects760.77 (0.65 to 0.91)*12Vitamin E†
Random effects810.76 (0.57 to 1.01)5Low quality trials
Random effects750.75 (0.58 to 0.97)*7High quality trials
Random effects620.79 (0.53 to 1.17)4Not supplied by pharmaceutical industry
Random effects860.67 (0.42 to 1.07)*3Supplied by pharmaceutical industry
Random effects760.72 (0.54 to 0.95)*7Primary prevention
Random effects550.79 (0.42 to 1.50)3Not supplied by pharmaceutical industry
Random effects820.63 (0.42 to 0.97)*4Supplied by pharmaceutical industry
Random effects800.79 (0.61 to 1.02)5Secondary prevention
Random effects620.79 (0.53 to 1.17)4Not supplied by pharmaceutical industry
Random effects820.73 (0.59 to 0.92)*8Supplied by pharmaceutical industry
Random effects520.95 (0.80 to 1.14)4β carotene
Fixed effects00.87 (0.59 to 1.28)3Selenium
Fixed effects431.02 (0.92 to 1.12)9Fatal myocardial infarction
NANA1.00 (0.75 to 1.33)1Vitamin B6
NANA1.00 (0.75 to 1.33)1Vitamin B12
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Table 3 (continued)
ModelHeterogeneity I2 (%)Relative risk (95% CI)No of trials
NANA1.00 (0.75 to 1.33)1Folic acid
Fixed effects00.57 (0.32 to 1.03)3Vitamin E†
NANA1.05 (0.95 to 1.17)1β carotene
NANA1.12 (0.43 to 2.87)1Selenium
Random effects890.83 (0.66 to 1.04)13Non-fatal myocardial infarction
Fixed effects221.08 (0.90 to 1.30)3Vitamin B6
Fixed effects11.03 (0.93 to 1.14)4Vitamin B12
Fixed effects11.03 (0.93 to 1.14)4Folic acid
Random effects00.85 (0.70 to 1.04)4Vitamin C†
Fixed effects00.57 (0.32 to 1.03)9Vitamin E†
Random effects520.95 (0.80 to 1.14)4β carotene
Fixed effects00.82 (0.53 to 1.27)3Selenium
Fixed effects00.97 (0.93 to 1.02)32Stroke
Fixed effects130.93 (0.85 to 1.01)12Vitamin B6
Fixed effects80.91 (0.80 to 1.03)5Vitamin B12
Fixed effects190.90 (0.79 to 1.01)7Folic acid
Fixed effects00.98 (0.88 to 1.09)4Vitamin C†
Fixed effects61.00 (0.88 to 1.13)5Vitamin D
Fixed effects201.00 (0.93 to 1.09)12Vitamin E†
Fixed effects00.98 (0.89 to 1.07)2β carotene
NANA1.09 (0.68 to 1.72)1Selenium
Fixed effects01.12 (0.97 to 1.30)5Transient ischaemic attack
Fixed effects01.12 (0.88 to 1.42)2Vitamin B6
Fixed effects01.12 (0.88 to 1.42)2Vitamin B12
Fixed effects01.12 (0.88 to 1.42)2Folic acid
NANA1.12 (0.96 to 1.42)1Vitamin D
Fixed effects00.93 (0.59 to 1.47)2Vitamin E†
NA=not applicable.
*P≤0.05.
†For subgroup meta-analysis of vitamin C and vitamin E, we used data from 2008 PHS2 article83 because data were not available in 2012 PHS article.
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Table 4| Efficacy of vitamin and antioxidant supplements in prevention of major cardiovascular events in subgroupmeta-analysis by various
factors
ModelHeterogeneity, I2 (%)Relative risk (95% CI)No of trialsFactor
Study design:
Fixed effects461.00 (0.98 to 1.02)45RDBPCT
Fixed effects00.98 (0.89 to 1.07)5OLRCT
Methodological quality:
Fixed effects450.99 (0.96 to 1.03)24High quality (Jadad score 5)
Fixed effects321.01 (0.98 to 1.03)23Low quality (Jadad score ≤4)
Duration of treatment (years):
Random effects520.97 (0.90 to 1.04)34<5
Fixed effects01.01 (0.98 to 1.03)16≥5
Funding source:
Fixed effects01.01 (0.96 to 1.07)5Pharmaceutical industry
Fixed effects421.00 (0.98 to 1.02)42Independent organisation
Supply source for supplements:
Fixed effects330.99 (0.97 to 1.02)29Pharmaceutical industry
Fixed effects471.01 (0.98 to 1.05)18Not pharmaceutical industry
Type of control:
Fixed effects461.00 (0.98 to 1.02)44Placebo
Fixed effects00.97 (0.89 to 1.06)6No placebo
No of participants in each trial:
Fixed effects400.97 (0.94 to 1.01)40<10 000
Fixed effects391.02 (0.99 to 1.04)10≥10 000
RDBPCT=randomised, double blind, placebo-controlled trial; OLRCT=open label, randomised controlled trial.
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Table 5| Efficacy of vitamin and antioxidant supplements given singly or combined with other vitamin or antioxidant supplements in
prevention of major cardiovascular events in subgroup meta-analysis
ModelHeterogeneity, I2 (%)Relative risk (95% CI)No of trialsFactor
Fixed effects421.00 (0.98 to 1.02)50All
Vitamin A:
———NAGiven singly
Random effects870.98 (0.45 to 2.16)2Combined with others
Vitamin B6:
———NAGiven singly
Fixed effects330.96 (0.92 to 1.01)16Combined with others
Random effects660.94 (0.73 to 1.21)5Low quality trials
Fixed effects10.96 (0.91 to 1.01)11High quality trials
Vitamin B12:
———NAGiven singly
Fixed effects370.99 (0.95 to 1.02)17Combined with others
Random effects660.94 (0.73 to 1.21)5Low quality trials
Fixed effects180.98 (0.95 to 1.02)12High quality trials
Folic acid:
Fixed effects471.02 (0.84 to 1.23)4Given singly
Fixed effects370.99 (0.95 to 1.02)17Combined with others
Fixed effects350.99 (0.95 to 1.02)21Given singly or combined
Fixed effects490.99 (0.90 to 1.08)8Low quality trials
Fixed effects180.98 (0.95 to 1.02)12High quality trials
Vitamin C*:
———NAGiven singly
Fixed effects160.99 (0.94 to 1.06)7Combined with others
Fixed effects440.99 (0.94 to 1.04)4Low quality trials
Fixed effects00.99 (0.88 to 1.11)3High quality trials
Vitamin D
Fixed effects110.95 (0.86 to 1.05)2Given singly
Fixed effects01.04 (0.99 to 1.10)5Combined with others
Fixed effects231.02 (0.98 to 1.07)7Given singly or combined
Fixed effects471.02 (0.98 to 1.08)5Low quality trials
Fixed effects01.01 (0.45 to 2.27)2High quality trials
Vitamin E*:
Random effects570.93 (0.85 to 1.01)10Given singly
Fixed effects150.99 (0.94 to 1.04)7Combined with others
Fixed effects440.97 (0.94 to 1.01)17Given singly or combined
Fixed effects430.99 (0.95 to 1.03)9Low quality trials
Fixed effects450.95 (0.90 to 1.00)†8High quality trials
β carotene:
Fixed effects311.02 (0.96 to 1.08)5Given singly
Random effects701.00 (0.81 to 1.23)6Combined with others
Random effects551.04 (0.96 to 1.12)11Given singly or combined
Fixed effects300.99 (0.95 to 1.03)6Low quality trials
Random effects641.13 (0.98 to 1.29)5High quality trials
Selenium:
Random effects700.34 (0.06 to 2.05)3Given singly
Fixed effects260.88 (0.72 to 1.08)4Combined with others
Fixed effects470.91 (0.77 to 1.06)7Given singly or combined
Fixed effects430.91 (0.73 to 1.12)4Low quality trials
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Table 5 (continued)
ModelHeterogeneity, I2 (%)Relative risk (95% CI)No of trialsFactor
NANA0.98 (0.77 to 1.24)1High quality trials
NA=not applicable.
*For subgroup meta-analysis of vitamin C and vitamin E, we used data from 2008 PHS2 article83 because data were not available in 2012 PHS article.
†P≤0.05.
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Figures
Fig 1 Flow diagram for identification of relevant clinical trials examining effect of vitamins and supplements in prevention
of cardiovascular disease
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Fig 2 Efficacy of vitamin and antioxidant supplements in prevention of major cardiovascular events in meta-analysis of 50
randomised controlled trials sorted in ascending order of number of participants
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Fig 3Efficacy of vitamin A supplements in prevention of major cardiovascular events in subgroupmeta-analysis of randomised
controlled trials
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Fig 4 Efficacy of vitamins B6 and B12 and folic acid supplements in prevention of major cardiovascular events in subgroup
meta-analysis of randomised controlled trials
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Fig 5 Efficacy of vitamins C, D, and E supplements in prevention of major cardiovascular events in subgroup meta-analysis
of randomised controlled trials. For subgroup meta-analysis of vitamin C and vitamin E, we used data from 2008 PHS2
article83 because data were not available in 2012 PHS article
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Fig 6Efficacy of β carotene and selenium supplements in prevention of major cardiovascular events in subgroupmeta-analysis
of randomised controlled trials
Fig 7 Efficacy of low dose vitamin B6 supplements in prevention of major cardiovascular events in subgroup meta-analysis
of randomised controlled trials by study quality according to Jadad scale
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Fig 8 Efficacy of vitamin E supplements in prevention of myocardial infarction in subgroup meta-analysis of randomised
controlled trials according to provider of supplements (pharmaceutical industry or other). For subgroup meta-analysis of
vitamin E, we used data from 2008 PHS2 article83 because data were not available in 2012 PHS article
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